Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 3 records in total 3
    records per page




    Non-alcoholic fatty liver disease MESHD ( NAFLD MESHD) and risk of hospitalization for Covid-19.

    Authors: Carolyn Bramante; Christopher J. Tignanelli; Nirjhar Dutta; Emma Jones; Leonardo Tamariz; Jeanne M Clark; Michael Usher; Genevieve Metlon-Meaux; Sayeed Ikramuddin; Ravi Prakash Madaiah; Peter Hart; Hemant Kulkarni

    doi:10.1101/2020.09.01.20185850 Date: 2020-09-02 Source: medRxiv

    Background: Covid-19 disease causes significant morbidity and mortality through increase inflammation MESHD and thrombosis MESHD. Non-alcoholic fatty liver disease MESHD and non-alcoholic steatohepatitis MESHD are states of chronic inflammation MESHD and indicate advanced metabolic disease MESHD. We sought to understand the risk of hospitalization for Covid-19 associated with NAFLD MESHD/NASH. Methods: Retrospective analysis of electronic medical record data of 6,700 adults TRANS with a positive SARS-CoV-2 PCR from March 1, 2020 to Aug 25, 2020. Logistic regression and competing risk were used to assess odds of being hospitalized. Additional adjustment was added to assess risk of hospitalization among patients with a prescription for metformin use within the 3 months prior to the SARS-CoV-2 PCR result, history of home glucagon-like-peptide 1 receptor agonist (GLP-1 RA MESHD) use, and history of metabolic and bariatric surgery (MBS). Interactions were assessed by gender TRANS and race. Results: A history of NAFLD MESHD/NASH was associated with increased odds of admission for Covid-19: logistic regression OR 2.04 (1.55, 2.96, p<0.01), competing risks OR 1.43 (1.09-1.88, p<0.01); and each additional year of having NAFLD MESHD/NASH was associated with a significant increased risk of being hospitalized for Covid-19, OR 1.86 (1.43-2.42, p<0.01). After controlling for NAFLD MESHD/NASH, persons with obesity HP obesity MESHD had decreased odds of hospitalization for Covid-19, OR 0.41 (0.34-0.49, p<0.01). NAFLD MESHD/NASH increased risk of hospitalization in men and women, and in all racial/ethnic subgroups. Mediation treatments for metabolic syndrome MESHD were associated with non-significant reduced risk of admission: OR 0.42 (0.18-1.01, p=0.05) for home metformin use and OR 0.40 (0.14-1.17, p=0.10) for home GLP-1RA use. MBS MESHD was associated with a significant decreased risk of admission: OR 0.22 (0.05-0.98, p<0.05). Conclusions: NAFLD MESHD/NASH is a significant risk factor for hospitalization for Covid-19, and appears to account for risk attributed to obesity HP obesity MESHD. Treatments for metabolic disease mitigated risks from NAFLD MESHD/NASH. More research is needed to confirm risk associated with visceral adiposity, and patients should be screened for and informed of treatments for metabolic syndrome MESHD.

    Poor Outcomes in Patients with Cirrhosis HP Cirrhosis MESHD and COVID-19

    Authors: Shalimar; Anshuman Elhence; Manas Vaishnav; Ramesh Kumar; Piyush Pathak; Kapil Dev Soni; Richa Aggarwal; Manish Soneja; Pankaj Jorwal; Arvind Kumar; Puneet Khanna; Akhil Kant Singh; Ashutosh Biswas; Neeraj Nischal; Lalit Dhar; Aashish Choudhary; Krithika Rangarajan; Anant Mohan; Pragyan Acharya; Baibaswata Nayak; Deepak Gunjan; Anoop Saraya; Soumya Mahapatra; Govind Makharia; Anjan Trikha; Pramod Garg

    doi:10.21203/rs.3.rs-40220/v1 Date: 2020-07-06 Source: ResearchSquare

    Background and AimThere is a paucity of data on the clinical presentations and outcomes of Coronavirus disease MESHD 2019(COVID-19) in patients with underlying liver disease MESHD. We aimed to summarize the presentations and outcomes of COVID-19 positive patients and compare with historical controls.MethodsPatients with known chronic liver disease MESHD who presented with superimposed COVID- 19(n=28) between 22nd April and 22nd June 2020 were studied. Seventy-eight cirrhotic patients from historical controls were taken as comparison group.ResultsA total of 28 COVID patients- two without cirrhosis HP cirrhosis MESHD, one with compensated cirrhosis HP cirrhosis MESHD, sixteen with acute decompensation (AD), and nine with acute-on-chronic liver failure MESHD( ACLF MESHD) were included. The etiology of cirrhosis HP cirrhosis MESHD was alcohol(n=9), non-alcoholic fatty liver disease MESHD(n=2), viral(n=5), autoimmune hepatitis MESHD hepatitis HP(n=4), and cryptogenic cirrhosis HP(n=6). The clinical presentations included complications of cirrhosis HP cirrhosis MESHD in 12(46.2%), respiratory symptoms in 3(11.5%) and combined complications of cirrhosis HP cirrhosis MESHD and respiratory symptoms in 11(42.3%) patients. The median hospital stay was 8(7-12) days. The mortality rate in COVID-19 patients was 42.3%(11/26), as compared to 23.1%(18/78) in the historical controls(p=0.077). All COVID-19 patients with ACLF(9/9) died compared to 53.3%(16/30) in ACLF of historical controls(p=0.015). Mortality rate was higher in COVID patients with compensated cirrhosis HP cirrhosis MESHD and AD MESHD as compared to historical controls 2/17(11.8%) vs 2/48(4.2%), though not statistically significant (p=0.278). Requirement of mechanical ventilation independently predicted mortality (hazard ratio, 13.68). Both non-cirrhotic patients presented with respiratory symptoms MESHD and recovered uneventfully.ConclusionCOVID-19 is associated with poor outcomes in patients with cirrhosis HP cirrhosis MESHD, with worst survival rates in ACLF. Mechanical ventilation is associated with a poor outcome.

    COVID-19 Comorbidity and Metabolic Syndrome MESHD: Is There a Molecular Basis?

    Authors: Madhurima Basu; Chinmay Saha; Kamalika Roy Choudhury; Susmita Dutta; Sujoy Ghosh; Subhankar Chowdhury; Satinath Mukhopadhyay; Nitai P. Bhattacharyya

    id:10.20944/preprints202006.0245.v1 Date: 2020-06-21 Source: Preprints.org

    The risk factors associated with COVID-19 related severity, morbidity, and mortality, i.e., obesity HP obesity MESHD (often associated with NAFLD MESHD), hyperglycemia HP hyperglycemia MESHD, hypertension HP hypertension MESHD and dyslipidemia all cluster MESHD together as metabolic syndrome MESHD ( MetS MESHD). Instead of studying association of these risk factors with COVID-19, it makes sense studying the association between MetS MESHD on one hand and COVID-19 on the other. This study explores a molecular basis underpinning the above association. Severity of COVID-19 patients with MetS MESHD could be due to functional alterations of host proteins due to their interactions with viral proteins. We collected data from Enrichr (https://amp.pharm.mssm.edu/Enrichr/), DisGeNET (https://www.disgenet.org/) and others and carried out enrichment analysis using Enrichr. Various biological processes and pathways associated with viral protein interacting partners are known to involve in metabolic diseases MESHD. The molecular pathways underlying insulin resistance HP, insulin signaling and insulin secretion are not only involved in diabetes MESHD but also in CVD and obesity HP obesity MESHD (associated with non-alcoholic fatty liver disease MESHD; NAFLD MESHD). Lipid metabolism/lipogenesis, fatty acid oxidation and inflammation MESHD are associated with MetS MESHD. Viral interacting host proteins are associated and enriched with terms like hyperglycemia HP hyperglycemia MESHD, coronary artery disease MESHD, hypertensive disease MESHD related to CVD and liver diseases MESHD in DisGeNET. Association of viral interacting proteins with disease-relevant biological processes, pathways and disease-related terms suggests that altered host protein function following interaction with viral proteins might contribute to frequent occurrence and/or severity of COVID-19 in subjects with MetS MESHD. Such analysis not only provides a molecular basis of comorbidity but also incriminates host proteins in viral replication, growth and identifies possible drug targets for intervention.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.